North Carolina expansion Coriolis Pharma is expanding with a new U.S. headquarter and laboratory in Morrisville, NC, and a grand opening in RTP. This creates a foothold in a key biotech hub, presenting immediate cross-sell opportunities for formulation development, lyophilization, analytics, and GMP/non-GMP services to nearby biotechs, CROs, and biopharma companies.

Full-spectrum CRDO As a globally operating contract research and development organization focused on formulation development, lyophilization, analytics, and support for biopharmaceutical modalities (proteins, peptides, nucleic acids, gene and cell therapies, vaccines, virus-like particles), Coriolis offers end-to-end services that can replace or augment clients’ internal capabilities across development to commercialization.

Biotech partnerships Strategic collaborations already in place with industry players such as MassBio and notable investment in U.S. lab infrastructure indicate a growth-oriented partner open to co-development, outsourcing, and long-term programs, suggesting sales opportunities for throughput expansion, platform services, and joint ventures.

GMP and non-GMP analytics Coriolis highlights expertise in both GMP and non-GMP analytics for a wide range of products, a compelling value proposition for clients needing adaptable testing, stability studies, quality by design, and regulatory-ready data packages aligned with global standards.

Capital-backed growth Significant investment in a new North Carolina facility and ongoing expansion, coupled with a revenue range of several tens of millions, signals financial stability and capacity to take on larger or multiple concurrent programs, enabling sales teams to propose scalable engagements and capacity guarantees.